Navigation Links
Promising Data Presented on GenVec Malaria Program
Date:11/14/2012

s such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expen
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
2. New 3-D transistors promising future chips, lighter laptops
3. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
4. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
5. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Startling results in synthetic chemistry presented in Nature Chemistry
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
11. GenVec Achieves Second Milestone in Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
(Date:4/16/2015)... 16, 2015  EMD Serono today announced the ... Germany , appointed Alise Reicin ... Global Clinical Development.  Dr. Reicin brings extensive research ... Oncology and Immunology. She is an accomplished pharmaceutical ... a Vice President in various capacities across R&D ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... 3 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... 26th Annual Healthcare Conference will be webcast on ... Hrusovsky, President and CEO of,Caliper, will be providing ... can be accessed at, http://www.metameetings.com/webcasts/jpmorgan/healthcare08/ . An archived,presentation ...
... MEDX ) announced today that it is scheduled ... 10:30 a.m. ET on Tuesday, January,8, 2008. The event ... the,Investor Relations section of the Medarex Web site at ... be available following the event., About Medarex, ...
... Mass., Jan. 3 Mersana, a cancer therapeutics,company, ... as Chairman of,the Company,s Board of Directors. Mr. ... a significant record of accomplishment over a,30-year industry ... welcome Boyd Clarke as Chairman of our Board,of ...
Cached Biology Technology:Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... University biologist has been awarded over $2.3 million from ... of the human pathogen chlamydia in hopes of finding ... disease in the United States. David E. Nelson, ... Arts and Sciences, Department of Biology, and researchers in ...
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... buzz of the golden-winged warbler,s song might not sound like ... population of this little, gray songbird with bright yellow patches ... since 1966. And, as of yet, it remains unprotected by ... dire situation for the warbler, and Ronald Canterbury wants people ...
Cached Biology News:In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 2In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 3To drive infections, a hijacking virus mimics a cell's signaling system 2UC research: Saving habitat key to songbird's survival 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... polyclonal to FbxL7 The F ... which it was originally observed, is ... binds SKP1. F-box proteins are components ... called SCFs (SKP1, cullin, F-box proteins), ...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Biology Products: